Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Lisa Baumbach- Reardon

Lisa Baumbach- Reardon

Translational Genomics Research Institute, USA

Title: Rare disease research – opportunities and challenges

Biography

Biography: Lisa Baumbach- Reardon

Abstract

Human Rare Diseases, also referred to as an orphan disease, is any disease that affects a small percentage of the population. Most rare diseases are genetic, and thus are present throughout the person's entire life, even if symptoms do not immediately appear. Many rare diseases appear early in life, and about 30 percent of children with rare diseases will die before reaching their fifth birthday. No single cutoff number has been agreed upon for which a disease is considered rare. A disease may be considered rare in one part of the world, or in a particular group of people, but still be common in another. There is no single, widely accepted definition for rare diseases, which places constant demands on disease advocates, parents, clinicians and researchers to bring their concerns to national agencies regarding recognition of the disorder and treatment options for relatively rare diseases. Out research group has had the unique opportunity to identify a rare genetic disorder, X-Linked Spinal Muscular Atrophy (XL-SMA), and to work with clinicians and families throughout the world to identify these rare families. We have collected blood samples from family members to perform DNA linkage analysis, and finally, disease gene identification in a subset of these families. Surprising, as DNA identification technologies have developed, so has our sub-classification of even rarer “genetic” disorders evolved, demonstrating the additive strength of analyzing clinical phenotypes to causative genotypes which may well be overlapping in primary or secondary disease pathways.